Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patients
Phase 3
- Conditions
- type 2 diabetes mellituds
- Registration Number
- JPRN-UMIN000032848
- Lead Sponsor
- Osaki Citizen Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Anti-glutamic acid decarboxylase (GAD) antibody above normal range. 2) HBs antigen or/end HCV antibody is positive. 3)Patients who discontinue the use of SGLT2 inhibitors during the period. 4)Patients who were taking acarbose and/or herbal medicines.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of HbA1c decrese of Body Weight
- Secondary Outcome Measures
Name Time Method Improvement of liver function Improvement of fatty liver